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Reduction of the opioid analgesia in diabetic neuropathic pain (DNP) results from
µ-opioid receptor (MOR) reserve reduction. Herein, we examined the antinociceptive
and antiallodynic actions of a novel opioid agonist 14-O-methymorphine-6-O-sulfate
(14-O-MeM6SU), fentanyl and morphine in rats with streptozocin-evoked DNP of 9–
12 weeks following their systemic administration. The antinociceptive dose-response
curve of morphine but not of 14-O-MeM6SU or fentanyl showed a significant right-shift
in diabetic compared to non-diabetic rats. Only 14-O-MeM6SU produced antiallodynic
effects in doses matching antinociceptive doses obtained in non-diabetic rats. Co-
administered naloxone methiodide (NAL-M), a peripherally acting opioid receptor
antagonist failed to alter the antiallodynic effect of test compounds, indicating the
contribution of central opioid receptors. Reduction in spinal MOR binding sites and loss
in MOR immunoreactivity of nerve terminals in the spinal cord and dorsal root ganglia in
diabetic rats were observed. G-protein coupling assay revealed low efficacy character
for morphine and high efficacy character for 14-O-MeM6SU or fentanyl at spinal or
supraspinal levels (Emax values). Furthermore, at the spinal level only 14-O-MeM6SU
showed equal efficacy in G-protein activation in tissues of diabetic- and non-diabetic
animals. Altogether, the reduction of spinal opioid receptors concomitant with reduced
analgesic effect of morphine may be circumvented by using high efficacy opioids, which
provide superior analgesia over morphine. In conclusion, the reduction in the analgesic
action of opioids in DNP might be a consequence of MOR reduction, particularly in
the spinal cord. Therefore, developing opioids of high efficacy might provide analgesia
exceeding that of currently available opioids.
Keywords: diabetes, neuropathic pain, opioid efficacy, 14-O-methylmorphine-6-O-sulfate, morphine, fentanyl
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INTRODUCTION
Neuropathic pain (NP) is a chronic pain condition that limits
patients to fully achieve their daily tasks. Consequently, NP
has significant impact on the economic welfare of the society
(Bouhassira et al., 2008; Gaskin and Richard, 2012). Therefore, to
find drugs satisfactorily treating NP is a major clinical goal. The
management of severe acute to moderate pain including cancer
pain can be achieved by opioids, however, opioid effectiveness
in the treatment of chronic NP is controversial (Wiffen et al.,
1996; Eriksen et al., 2006; Furlan et al., 2006; Derry et al., 2016;
Hoffman et al., 2017). At present, opioids are considered as a
second-to-third-line medication for NP. However, they can be
considered as first line drugs, when they may offer advantages
over the general first line drugs for instance in case of cancer
NP, an acute pain attack or during first line drug titration. Data
from in vivo experimental studies have reported on a significant
reduction in opioid antinociceptive efficacy in neuropathic
animals following systemic administration (Courteix et al., 1998;
Hama and Sagen, 2007). The loss in opioid antinociceptive
efficacy has also been reported following central (spinal or
supraspinal) administration in NP animals (Ohsawa and Kamei,
1997; Zurek et al., 2001). It was proposed that the impaired
opioid antinociception occurred as a consequence of the decrease
in opioid receptor reserve (Zhang et al., 1998). In addition,
the reduction in opioid receptor density in spinal tissues was
also demonstrated in diabetic animals (Courteix et al., 1998;
Shaqura et al., 2013).
Based on these observations, we hypothesize that the
reduction in MOR number in diabetic neuropathic pain (DNP) is
a crucial factor in the loss of analgesic effect of opioids. Recently,
we have demonstrated that opioids of high efficacy in contrast to
morphine could produce significant maximal effects (efficacy) in
isolated organs hosting low opioid receptor reserve (Al-Khrasani
et al., 2007; Riba et al., 2010; Lacko et al., 2012; Khalefa et al., 2013;
Zádor et al., 2017).
Thus, opioids of high intrinsic efficacy displaying spare
receptors might produce analgesic effects even though the
MOR reserve is low. In the past two decades our group has
paid attention to the efficacy of opioids, particularly to MOR
agonists (Al-Khrasani et al., 2007, 2012; Lacko et al., 2012;
Kiraly et al., 2015; Lackó et al., 2016; Zádor et al., 2017;
Balogh et al., 2018). These previous studies have proved the
high efficacy character for 14-O-methylmorphine-6-O-sulfate
(14-O-MeM6SU).
Therefore, the present study was aimed to examine the
antinociceptive and antiallodynic effects of the recently
synthetized 14-O-MeM6SU compared to the high efficacy
fentanyl and low efficacy morphine in a rat model of DNP. To
this extent, the experiments were carried out 9 and 12 weeks
following intraperitoneal (i.p.) streptozocin (STZ) treatment.
The number of MOR was also evaluated in dorsal root ganglia
(DRG) and dorsal horn tissues of diabetic and non-diabetic
rats. Finally, we measured G-protein coupled receptor activity
to determine the efficacy of test compounds in diabetic rat
spinal cord and brain homogenates. Prior to in vivo and in vitro
experiments, the change in the paw threshold, blood glucose
level, weight, as well as water- and food consumption of diabetic
and control rats was followed.
MATERIALS AND METHODS
Animals
Male Wistar rats of 200–300 g were used for STZ-induced
diabetes model. The animals were obtained from the local
Animal House (Semmelweis University, Budapest, Hungary).
The animals were kept in mesh bottomed cage (4, 5, or 6
animals/cage depending on the weight of animals) in a room
of 20 ± 2◦C temperature, 12-h/12-h light/dark cycle, in the
local animal house of the Semmelweis University, Department
of Pharmacology and Pharmacotherapy (Budapest, Hungary).
The type of the cage was eurostandard type IV. The floor
area is 1820 cm2. This type allows to keep 7 rats of 300 g
according to EU recommendation. Water and standard food were
available ad libitum. In the first series of experiments control
(vehicle treated) and diabetic (STZ treated) animals were kept
individually in mash bottomed cages making the measurement
of individual parameters possible.
All housing and experiments were performed in accordance
with the European Communities Council Directives
(2010/63/EU), the Hungarian Act for the Protection of Animals
in Research (XXVIII.tv. 32.§) and local animal care committee
(PEI/001/276-4/2013). All the researchers did the best effort to
minimize the number of animals and their suffering.
Chemicals
The morphine analog 14-O-methylmorphine-6-O-sulfate (14-O-
MeM6SU) was provided by the Department of Pharmaceutical
Chemistry, Semmelweis University (Budapest, Hungary) and
was synthesized and characterized as previously described
(Lacko et al., 2012). Naloxone methiodide (NAL-M), STZ
and clonidine-hydrochloride were obtained from Sigma-Aldrich
Ltd. (Budapest, Hungary) and morphine hydrochloride from
Alkaloida-ICN (Tiszavasvári, Hungary). Fentanyl was purchased
from Toronto Research Chemicals (North York, ON, Canada),
Tris-HCl, EGTA, NaCl, MgCl2 x 6H2O, GDP, the GTP analog
GTPγS, were purchased from Sigma-Aldrich Ltd. (Budapest,
Hungary). The MOR agonist enkephalin analog Tyr-D-Ala-
Gly-(NMe)Phe-Gly-ol (DAMGO) was obtained from Bachem
Holding AG (Bubendorf, Switzerland). Ligands were dissolved
in water and were stored in 1 mM stock solution at −20◦C for
in vitro tests. Ligands used for in vivo assays were dissolved in
saline or in the case of STZ ice cold distilled water prior to
the experiments.
The radiolabeled GTP analog, [35S]GTPγS (specific activity:
1000 Ci/mmol) was purchased from Hartmann Analytic (through
Izotóp Intézet Kft., Budapest, Hungary). The UltimaGoldTM MV
aqueous scintillation cocktail was purchased from PerkinElmer
(through Per-Form Hungária Kft., Budapest, Hungary). All
compounds were stored and handled as described in the product
information sheet.
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Streptozocin (STZ)-Induced Diabetic
Neuropathic Pain Model (Model of
Polyneuropathy)
Experimental Design
The experimental procedures for experiments designed to
assess the induction of hyperglycemia, allodynia, polydipsia,
polyphagia, weight change as well as the assessment of drug
antinociception are included in Figure 1.
Induction of Diabetes
We used STZ to induce diabetes. The animals were treated i.p.
with 60 mg/kg streptozocin in a 2.5 ml/kg volume. The STZ was
diluted in cold distilled water as described previously and the
solution was made less than 10 min before the injection to avoid
any degradation (Courteix et al., 1994; Rajaei et al., 2013). Vehicle
treated group was used as absolute control.
Measuring the Blood Glucose Levels of
Diabetic Animals
Blood glucose level was determined prior to and 72 h, 1, 3, 9,
and 12 weeks after STZ or vehicle treatments. Animals were
slightly anesthetized with 3% isoflurane in oxygen via nose cone
as described previously (Balogh et al., 2018). Then one drop of
blood was taken from the tail veins. Accu-Chek Active blood
glucose meter (Roche Diagnostics GmbH, Germany) was used
to measure blood glucose levels. The maximal measurable blood
glucose level value by blood glucose test is 33.3 mmol/l. Animals
with blood glucose level of 14 mmol/l or higher were considered
diabetic as described previously (Courteix et al., 1993).
Measuring of Animal Weight and the Consumption of
Food and Water of Diabetic Animals
In the first series of experiments control (vehicle treated) and
diabetic (STZ treated) animals were kept individually. Then,
the water and food consumption were measured separately for
each animal before and after the STZ treatment during 7 weeks
(Figure 1). In this period, the weight of the food and water was
measured each day for 4 weeks and two times a week for 3 weeks.
The consumed amount was calculated. The weight of the animals
were also measured during the 7 weeks period in the same way
and on the day of experiments. Thereafter, animals were kept in
groups until the day of experimentation.
Determination of Gastric Emptying in Diabetic and
Non-diabetic Rats
Gastric emptying was assessed by the phenol red method
as described earlier (Fülöp et al., 2005), with some minor
modifications. Briefly, after 24 h of fasting, diabetic and non-
diabetic rats received 1.5 ml of 1.5% methylcellulose solution
containing 0.5 mg/ml phenol red (a non-absorbable marker
compound) by intragastric gavage. After 20 min the rats were
sacrificed and the stomachs were removed after clamping the
pylorus and cardia. The content of stomach was mixed with 40 ml
of 0.1 N NaOH, then 0.6 ml mixture was added to 1.2 ml of
7.4% trichloroacetic acid solution to precipitate proteins. After
centrifugation (15 min, 3000 g) 1.2 ml of the supernatant was
added to 0.6 ml of 1 N NaOH, and the absorbance was read
spectrophotometrically in triplicates at 560 nm. Gastric emptying
(%) was calculated as follows: [1 – (absorbance of sample /
maximal absorbance)]× 100. Maximal absorbance was measured
by processing the test meal alone, as described above.
In a separate experiment, weight match animals were
treated either with saline, or with clonidine (0.1 mg/kg),
an alpha2 adrenoceptor agonist and well-known inhibitor
of gastric emptying, subcutaneously 30 min before the
methylcellulose administration.
Assessment of Neuropathic Pain by Dynamic Plantar
Aesthesiometer (DPA)
In order to determine the allodynia caused by advanced diabetes
we used the DPA (Ugo Basile, Italy) as described previously (de
Novellis et al., 2011) with slight modifications based on our the
pilot experiments. The animals were placed in the plastic cages of
the DPA once daily for 3 subsequent days (“handling”). Before
each experiment, animals were kept in these cages for at least
5 min before starting the measurement in order to habituate
them. The equipment raises a straight metal filament of 0.5 mm
diameter until it touches the hind paws. Then it puts pressure
on the paw with an increasing force from 1 to 50 g (cut off).
The maximal force applied by DPA is 50 g (as prescribed by
manufacturer instrument guide).
The paw pressure withdrawal thresholds (PPTs) were
measured and expressed in g, before and after the STZ treatment
on every 3rd week. In the first series of experiments, PPTs
were measured weekly after STZ treatment in order to detect
touch allodynia. PPTs of each hind paw were measured 3 times
alternately. Then, the average of PPT values of the two paws
were calculated for each animal. Vehicle treated and weight
match (i.e., animals with weights matching the diabetic ones)
groups were used as control. After determination of the time
of peak effect further analysis was made at that time point. An
animal was considered neuropathic, when the PPT value was at
least decreased by 20% compared to weight match animals as
described previously (Király et al., 2018).
It is important to note that significant change in the weight
of animals result in significant alteration in the PPTs (i.e., higher
weight elevates the threshold values, data not shown). This weight
change may contribute to the potential differences observed
between control and diabetic animals in PPTs. Therefore, to
justify this alteration, the use of weight match control animals
was necessary, to have a more exact analysis as also described
previously (Végh et al., 2017). Weight match animals were
handled and kept under the same conditions described for the
diabetic (STZ treated) and non-diabetic control (vehicle treated)
animals. The exception is that weight match animals were kept
only for at least 1 week prior to experiments. In addition, the
weight matched animals were also used to avoid lack of blindness
during the experiments, though the symptoms of diabetes can not
be fully masked.
Treatment of Neuropathic Animals
The test compounds were dissolved in saline in a volume
of 2.5 ml/kg body weight. Baselines of PPTs were measured
before subcutaneous (s.c.) agonist treatment. The opioid
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FIGURE 1 | Representative figure illustrating the experimental protocol. For each experiment different animals were used. For in vitro studies different groups
were used.
antagonist, NAL-M was co-administered with morphine and
14-O-MeM6SU. Solutions were prepared right before the
experiment (in less than 10 min). The experiments were
randomized and the experimenter was blind to the treatments.
Radio-Ligand Binding Assays
Membrane Preparations
Membranes were obtained from lumbar dorsal root ganglions
(DRGs) and spinal cord (L3-5), quickly frozen, and dissected into
the ventral and dorsal half, as described previously (Shaqura et al.,
2016; Mousa et al., 2017). DRGs and only the dorsal part of the
spinal cord were further processed for radioligand binding. The
tissues were placed immediately in ice cold assay buffer (50 mM
Tris-HCl, 1 mM EGTA, 5 mM MgCl2, pH 7.4), homogenized
with a Polytron homogenizer (Kinematica, Littau, Switzerland),
and centrifuged at 48,000 g at 4◦C for 20 min. The pellets were
resuspended in assay buffer followed by 10 min incubation at
37◦C to remove endogenous ligands. The homogenates were
centrifuged again at 48,000 g and resuspended in assay buffer.
Membranes were aliquoted and stored at−80◦C.
Opioid Receptor Binding
Specific binding of [3H]DAMGO was performed by incubating
50–100 µg of membrane protein of lumbar dorsal horn
with 0.1- 4 nM [3H]DAMGO in the presence or absence
of 10 µM unlabelled naloxone to determine non-specific
binding. Membranes were incubated for 1 h at 22◦C in assay
buffer. The reactions were terminated by rapid filtration under
vacuum through Whatman GF/B glass fiber filters, followed
by four washes with cold buffer (50 mM Tris–HCl, pH 7.4).
Bound radioactivity was determined by liquid scintillation
spectrophotometry (Perkin Elmer, Rodgau, Germany) at 60%
counter efficiency after overnight extraction of the filters in
3 ml of scintillation fluid. All experiments were performed
in duplicate and carried out at least five times. Bmax and
Kd values in saturation binding assays were determined by
nonlinear regression analysis of concentration-effect curves
using GraphPad Prism (GraphPad Software Inc., San Diego,
CA, United States).
Immunohistochemistry
Rats were deeply anesthetized with isoflurane and transcardially
perfused with 100 ml of phosphate buffered saline (PBS) pH
7.4, then followed by 500 ml of 4% (w/v) paraformaldehyde in
phosphate buffer pH 7.4. After perfusion, DRG and spinal cord
were removed from treated and control animals, postfixed in the
same fixatives for 90 min, and then cryo-protected overnight at
4◦C in PBS containing 10% sucrose. DRGs (10 µm thick) were
mounted onto gelatin coated slides. DRG mounted or spinal
cord floating tissue sections were incubated with the following
primary antibody rabbit polyclonal MOR antibody (1:1,000,
Gramsch Laboratories, Schwabhausen, Germany). The tissue
sections were washed with PBS prior to incubation with Alexa
Fluor 594 donkey anti-rabbit secondary antibody (Invitrogen,
Germany). Finally, the tissues were washed in PBS, mounted on
vectashield (Vector Laboratories, Burlingame, CA, United States)
and viewed under Zeiss LSM 510 laser scanning microscope
(Carl Zeiss, Göttingen, Germany). To demonstrate specificity
of staining, the following controls were included as mentioned
in detail elsewhere (Endres-Becker et al., 2007; Mousa et al.,
2013): (1) Preabsorption of the primary antibody against MOR
was verified by preabsorption with 5 µg/ml of synthetic peptide
antigen for MOR (Gramsch Laboratories, Germany), for 24 h
at 4◦C; (2) Omission of either the primary antisera or the
secondary antibodies.
Quantification of Immunostaining
The method of quantification of DRG and spinal cord dorsal
horn immunostaining has been described in detail elsewhere
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(Shaqura et al., 2013). Briefly, the total number of MOR-IR
neurons was counted in each area (320 µm2) and this number
was divided by the total number of neurons in each DRG within
the same area and represented as percentages. For quantification
of MOR immunoreactivity in the dorsal horn of spinal cord
images of red immunofluorescence were obtained using a Zeiss
LSM 510 laser scanning microscope and the image-analysis
software package 2.5 SP2 from Zeiss was applied to quantify
changes in immunodensities as described in detail elsewhere
(Shaqura et al., 2013). The settings of the confocal microscope
were established using a control section and kept unchanged for
all subsequent acquisitions. Six to eight images were sampled
per animal. Images were thresholded to exclude background
fluorescence and gated to include intensity measurements only
from positively stained nerve fibers. For image analysis, a
standardized area was positioned over the Rexed laminae 1-5 of
all groups to determine the mean product of the area (100 µm2)
and mean intensity of pixels within the threshold value and to
calculate the integrated optical intensity (product of area and
mean intensity). The mean value of control was considered as
100%. Five rats per group were used for analysis. Data were
expressed as means ± SEM. Scale bar = 20 µm for DRG and
40 µm for spinal cord section.
G-Protein Activity Assays
Membrane Preparations
Rats were decapitated and their brains and whole spinal cords
were quickly removed and were prepared for receptor binding
assays as previously reported (Benyhe et al., 1997; Zádor et al.,
2014). In brief, first the brain and spinal cord were homogenized,
centrifuged in ice-cold 50 mM Tris-HCl (pH 7.4) buffer and
incubated at 37◦C for 30 min in a shaking water-bath (for details
see Benyhe et al., 1997). After incubation the centrifugation was
repeated as described before and the final pellet was suspended
in ice-cold TEM (Tris-HCl, EGTA, MgCl2) buffer and stored at
−80◦C for further use.
Functional [35S]GTPγS Binding Assays
In [35S]GTPγS binding experiments the GDP→GTP exchange of
the Gαi/o protein by a radioactive, non-hydrolysable GTP analog,
[35S]GTPγS is measured. The nucleotide exchange is measured
in the presence of a given ligand in increasing concentrations to
measure ligand potency and the maximal efficacy (Strange, 2010).
The functional [35S]GTPγS binding experiments were
performed as previously described (Sim et al., 1995; Traynor and
Nahorski, 1995), with some modifications. Briefly, the rat brain
and spinal cord membrane homogenates containing ∼10 µg/ml
protein were incubated at 30◦C for 60 min in Tris-EGTA buffer
(pH 7.4) composed of 50 mM Tris-HCl, 1 mM EGTA, 3 mM
MgCl2, 100 mM NaCl. The incubation mixture contained 0.05
nM [35S]GTPγS, increasing concentrations (0.1 nM–10 µM) of
14-O-MeM6SU, fentanyl or morphine and excess GDP (30 µM).
The final volume of the incubation mixture was 1 ml.
Total binding was measured in the absence of the test
compounds, while non-specific binding was determined in the
presence of 10 µM unlabeled GTPγS. The bound and unbound
[35S]GTPγS were separated by rapid filtration under vacuum
(Brandel M24R Cell Harvester), and washed three times with
5 ml ice-cold 50 mM Tris-HCl through Whatmann GF/B
glass fibers (GE Healthcare Life Sciences through Izinta Kft.,
Budapest, Hungary). The radioactivity of the filters was detected
in UltimaGoldTM MV aqueous scintillation cocktail with Packard
Tricarb 2300TR liquid scintillation counter. [35S]GTPγS binding
experiments were performed in triplicates and repeated at
least three times.
Statistical Analysis
In vivo Assays
For the analysis of mechanical pain thresholds of diabetic
animals one-way or two-way ANOVA followed by Newman–
Keuls post hoc test was applied. Likewise, in the case of weight
change, water- and food consumption.
Dose response curves: dose response curves of percent
inhibition of nociceptive response were constructed for each
compound in rats 9 weeks after STZ treatment. Also dose
response curves of percent inhibition of nociceptive response
were calculated in weight matched non-diabetic rats for each
tested dose of test compounds. The percentage change of
PPT was determined in diabetic and weight matched non-
diabetic rats as follows: effect (%) = (PPT(after treatment) -
PPT(before treatment))/PPT(before treatment).
Then, the effective dose producing 30% effect (ED30)
was calculated from log-linear regression for each test
compound in diabetic and weight matched non-diabetic
rats. To analyze the changes in antinociceptive potency of
test compounds, the calculated ED30 values were compared
(ED30diabetic/ED30non−diabetic).
The antiallodynic effects of test compounds were analyzed by
one-way ANOVA followed by Newman–Keuls post hoc test at the
9th and 12th week. Weight match animals were used as absolute
control in DPA measurement. Vehicle treated group was used as
control in order to decide if the applied treatment significantly
influenced the parameters.
Results were considered statistically significant when P< 0.05.
All the analyses were performed with a professional statistical
software: GraphPad Prism 6.0 (GraphPad Software Inc., San
Diego, CA, United States).
G-Protein Activity and Radioligand Binding Assays
The specific binding of [35S]GTPγS was calculated by the
subtraction of non-specific binding from total binding and
was given in percentage. Data was normalized to total specific
binding, which was settled 100% and also represents the level
of basal activity of the G-protein. Experimental data were
presented as means ± SEM in the function of the applied ligand
concentration range in logarithm form. Points were fitted with
the professional curve fitting program, GraphPad Prism 5.0
(GraphPad Prism Software Inc., San Diego, CA, United States),
using non-linear regression, applying the ‘Sigmoid dose-
response’ equation to determine the maximum G-protein efficacy
(Emax) and ligand potency (EC50).
For the analysis of Emax values and the comparison of
individual concentration points within the concentration curves
two-way ANOVA with uncorrected Fisher’s LSD post hoc test was
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applied. Statistical analysis was performed with GraphPad Prism
6.0 program; significance was accepted at P < 0.05 level.
RESULTS
The Development of Diabetic Symptoms
and Neuropathic Pain (Allodynia) in STZ
Treated Rats
Significant increase in blood glucose concentration of
STZ-treated rats compared to vehicle treated animals was
achieved 72 h following intraperitoneal STZ injections.
This hyperglycaemia was maintained during the entire
experimental period (9-12 weeks) indicating the development of
diabetes (Figure 2A).
Also significant decrease in PPTs was achieved at the 3rd
week following STZ injection indicating the development of
mechanical allodynia (Figure 2B). This symptom is a key
feature in the diagnosis of neuropathic pain. Figure 2 depicts
that at the 9th and 12th week, diabetic animals developed
the lowest nociceptive thresholds that were significantly lower
compared to the baseline measured prior to STZ-treatment,
indicating the peak of allodynia. No significant difference in
developed allodynia was observed between the 9th and 12th
week following STZ-treatment. Therefore, in our subsequent
studies the antinociceptive action of test compounds, as well
as MOR functioning, were analyzed 9 and 12 weeks after
induction of diabetes.
Water intake of STZ treated rats was significantly
increased in comparison with the vehicle treated group
48 h following treatment. The food consumption of rats with
hyperglycaemia reached a significant increase 5 days after
treatment (Supplementary Figure 1). Diabetic rats gained
significantly less body weight compared to age matched animals.
Therefore, weight matched non-diabetic rats were used for a
comparison in nociceptive thresholds. In addition, we found no
differences between the rates of gastric emptying in 12-weeks
diabetic (80 ± 2%, n = 23) and non-diabetic rats (82 ± 2%,
n = 20), whereas 0.1 mg/kg clonidine, an alpha2-adrenoceptor
agonist used as a positive control, markedly delayed the emptying
in weight-matched control animals (55 ± 2%, n = 7, p < 0.01 vs.
saline-treated rats).
Advanced Diabetes Impairs the
Antinociceptive Effect of Systemic
Morphine but Not 14-O-MeM6SU or
Fentanyl in Rats
Prior to evaluation of the antinociceptive and anti-allodynic
effects, the peak antinociceptive effects of 14-O-MeM6SU and
morphine were established (60 min for 14-O-MeM6SU, 10 min
for fentanyl and 30 min for morphine; Supplementary Figure 2).
Thus, these times of peak effects were chosen for further analysis
in the entire pain study by DPA.
The calculated ED30 values of 14-O-MeM6SU were 434 and
335 nmol/kg for diabetic and non-diabetic animals, respectively.
The ED30 values of fentanyl were 41 and 54 nmol/kg in the
same order. In the case of morphine the ED30 values were
20692 and 6589 nmol/kg for diabetic and non-diabetic animals,
respectively. Based on the calculated ED30 values there was
no significant change in the antinociceptive effect of 14-O-
MeM6SU or fentanyl (the value of ED30diabetic/ED30non−diabetic
was 1.3 for both compounds). On the other hand, morphine
was 7 times less effective in diabetic, than non-diabetic
animals (ED30diabetic/ED30non−diabetic) (Figure 3). These data
also indicate that 14-O-MeM6SU displayed a 48 times and
fentanyl 505 times higher potency than morphine in diabetic
conditions based on the compared ED30 values.
The Antiallodynic Effects of Systemic
14-O-MeM6SU, Fentanyl and Morphine
in Diabetic Rats
The present data were obtained 9 and 12 weeks following STZ
treatment that is 6 and 9 weeks after the significant appearance of
allodynia, a major sign of painful diabetic neuropathy.
Subcutaneous 14-O-MeM6SU (253, 506, and 1012 nmol/kg),
fentanyl (25, 50, and 100 nmol/kg) and morphine (10000, 20000,
and 40000 nmol/kg) were tested for their antiallodynic actions
in diabetic rats with allodynia (Figure 4). 14-O-MeM6SU in all
tested doses significantly ameliorated the allodynia (Figure 4A),
whereas fentanyl and morphine only at a higher dose (100
and 40000 nmol/kg, respectively) attenuated the allodynia
significantly (Figures 4B,C).
When we compared the effects of 14-O-MeM6SU and
fentanyl or morphine doses in diabetic and non-diabetic
rats, morphine in lower doses (from 2500 nmol/kg) induced
significant antinociceptive actions in naïve (weight matched)
rats. 14-O-MeM6SU at the 253 nmol/kg dose, which already
produced antiallodynic effects in diabetic rats, failed to show
any significant antinociceptive action in naïve rats. However,
at higher doses (506 nmol/kg) it produced antinociception in
naïve rats. Interestingly, fentanyl showed partial but significant
antinociceptive effect in naïve rats in the doses of 25 and
50 nmol/kg, doses that failed to alter the thresholds of diabetic
animals. This means that 14-O-MeM6SU, but not fentanyl or
morphine did produce antiallodynic effects in certain doses
devoid of antinociception in naïve rats. This effect might
be attributed to the decrease in the opioid receptors, which
in turn affects the action of test compounds but not that
of 14-O-MeM6SU.
We further analyzed the lowest antiallodynic dose of 14-O-
MeM6SU and morphine (253 and 40000 nmol/kg, respectively)
at 12th weeks advanced diabetic rats. Both compounds produced
antiallodynic effects in accordance with 9th week data at the same
doses (data not shown).
The Antagonist Effect of Coadministered
NAL-M on the Systemic Antinociceptive
Effect of 14-O-MeM6SU or Morphine in
Diabetic Rats
The antagonist effect of the peripherally acting opioid antagonist
NAL-M (10.6 µmol/kg, s.c.) was tested against s.c. 14-O-
MeM6SU and morphine doses producing antiallodynic effects.
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FIGURE 2 | The changes in blood glucose levels in mmol/ml (A), and hind paw withdrawal thresholds (B) in grams prior to and after STZ- or vehicle treatments.
Animals not matching predefined criteria for diabetic neuropathy were excluded from experiments (at least 14 mmol/ml blood glucose level and at least 20%
decrease in PPT compared to weight matched animals). Figure represents data from one series of experiments. Each value represents the mean ± SEM. ∗p < 0.05
vs. the signed groups (one way ANOVA followed by Newman–Keuls post hoc test).
In these experiments NAL-M failed to alter the antiallodynic
action of test compounds (Figure 5), indicating the contribution
of the central nervous system. NAL-M alone had no effect (n = 5,
data not shown).
Persistent Hyperglycemia Reduced MOR
Immunoreactivity in Spinal Cord and
DRG as Well as Binding Sites in the
Spinal Cord of Rats
Constant hyperglycemia resulted in apparent decrease in the
number of MOR positive DRG neurons in rats developed
allodynia (Figure 6). In parallel, there is apparent reduction in the
MOR immunoreactivity within superficial layer of dorsal horn in
spinal cord of diabetic rats (Figure 6).
Indeed, the radioligand binding assay demonstrated that
the maximal of [3H]DAMGO by membrane spanning MOR
(Bmax) was significantly decreased in the dorsal horn of
diabetic rats (13.11 ± 1.85 fmol/mg) compared to controls
(23.55 ± 4.36 fmol/mg) (P < 0.001; Figure 7). The dissociation
constant (Kd) was 0.49 ± 0.18 for diabetic and 0.29 ± 0.17 for
control rats. These data indicate no significant difference between
diabetic and control rats in the affinity of DAMGO for MOR.
The G-Protein Coupling Activity in
Presence of 14-O-MeM6SU, Fentanyl or
Morphine in Spinal Cord Homogenates
Prepared From Diabetic or Control Rats
MOR specific G-protein coupling was measured by MOR
agonist-stimulated [35S]GTPγS binding assay. 14-O-MeM6SU
produced similar G-protein coupling in spinal cord tissues from
STZ or vehicle treated rats after 9 or 12 weeks (Figure 8). On
the other hand, fentanyl and morphine showed a significantly
reduced efficacy (Emax) of G-protein coupling in spinal cord
tissues of diabetic rats. The Emax of morphine showed a
significant decrease in the samples of 9th and 12th week, whereas
in the case of fentanyl the decrease was apparent in the 12th
week’s samples, in accordance with our previous data (Shaqura
et al., 2013). The calculated Emax values for test compounds
are presented in Table 1. The reduction in [35S]GTPγS specific
binding of morphine and fentanyl was also observed between
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FIGURE 3 | Dose-response curves of 14-O-MeM6SU (A), fentanyl (B) and
morphine (C) in diabetic and non-diabetic animals obtained with DPA. Data
are represented as mean ± SEM (n = 5–10).
certain concentration points of the concentration-response
curves (Figure 8). In general, 14-O-MeM6SU and fentanyl
showed significantly higher efficacy than morphine in all of the
spinal cord samples as indicated by the Emax values (Table 1).
Taken together, no difference exists in 14-O-MeM6SU-stimulated
coupling but it does exist in fentanyl- and morphine-stimulated
coupling between diabetic and control rats.
The G-Protein Coupling Activity in
Presence of 14-O-MeM6SU, Fentanyl or
Morphine in Brain Homogenates
Prepared From Diabetic or Control Rats
MOR G-protein coupling in the presence of 14-O-MeM6SU,
fentanyl or morphine was also determined in brain membrane
homogenates from STZ or vehicle treated rats. Neither
compounds showed significant differences in maximal efficacy
(Emax) and ligand potency (EC50) 9 or 12 weeks after STZ
treatment compared to control samples (Table 2 and Figure 9).
Additionally, in the control brain samples, 14-O-MeM6SU
and fentanyl showed significantly higher maximum efficacy
compared to morphine, whereas in the STZ treated brain samples
of the 9th week this significance disappeared, though the tendency
remained (Table 2 and Figure 9).
DISCUSSION
In the present study, we have examined the opioid
antinociceptive-antiallodynic efficacy in the mitigation of
rat neuropathic pain by three MOR agonists, namely, 14-O-
MeM6SU, fentanyl and morphine. The test compounds display
different pharmacological character in term of the efficacy
(Lacko et al., 2012; Shaqura et al., 2013). The analgesic effects
of currently available opioid analgesics in the management of
neuropathic pain is a matter of controversy in both clinical
practice and opioid research. Nevertheless, opioids and a related
compound, tramadol are considered as second line agents in the
management of painful diabetic neuropathy (Moulin et al., 2014).
It is noteworthy to mention that opioids in painful conditions
like NP due to cancer, or acute NP, are considered as first line
agents, and may also be useful to achieve fast pain relief during
titration of the conventional first line medications (Dowell
et al., 2016). The majority of opioids available for clinical use
produce their analgesic effects by activation of MOR. In animal
models of diabetes, the MOR reserve has been reported to be
reduced in rats of 2–3 weeks diabetes (Kou et al., 2016). Herein,
we paid attention to the impact of persistent hyperglycaemia
(9–12 weeks) on MOR-mediated antinociception by 14-O-
MeM6SU, fentanyl and morphine in rats. To the best of our
knowledge, this is the first work that reports on the antiallodynic
effect of the recently synthetized opioid agonist of high efficacy,
14-O-MeM6SU compared to that of opioids of high clinical
values, fentanyl and morphine on DNP in rats following systemic
administration (Lacko et al., 2012).
The first task was to follow the changes in blood glucose
level and development of allodynia for 12 weeks period following
STZ-treatment. STZ is a diabetogenic drug commonly used for
inducing diabetes. It’s diabetogenic action is a result of β-cell
destruction as proved by our and other previous works (Courteix
et al., 1993, 1994; Shaqura et al., 2013). In the present work
animals with (≥14 mmol/l) blood glucose level were considered
diabetics as described previously (Courteix et al., 1993). We have
measured significant allodynia 3 weeks following STZ treatment
that peaked at the 9th-12th week (Figure 2). These symptoms
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FIGURE 4 | The systemic antinociceptive effect of 14-O-MeM6SU (A), fentanyl (B) and morphine (C) in STZ treated diabetic rats with neuropathy on DPA test
following systemic (s.c.) administration at 9th week after STZ injection. Data were obtained 60 min after the injection of 14-O-MeM6SU, 10 min after fentanyl injection
and 30 min in the case of morphine injection (time of peak effect). Each value represents the mean in grams ± SEM. ∗p < 0.05 vs. diabetic baseline and saline
treated group. #p < 0.05 vs. weight match control group (one way ANOVA followed by Newman–Keuls post hoc test).
are indicative for development of DNP and in accordance with
previous studies (Courteix et al., 1993; Goyal et al., 2016).
In addition other symptoms related to development of
diabetes such as polydipsia, polyphagia and weight change were
also assessed. In this series of experiment the latter parameters
were only determined during the first 7 weeks following
STZ injection (Supplementary Figure 1). To carry out such
experiments animals were kept individually. The assessment of
these parameters was ended on the 7th week. The purpose was
to exclude the isolation stress of the rats when we assessed
analgesia. Generally, rodents prefer some form of group living.
It is well known that stress is significantly reduced in rats
that are housed in groups compared with rats housed alone
(Murínová et al., 2017). We also paid attention to the impact of
diabetes in gastrointestinal function. Although both acute and
chronic hyperglycemia can impair the gastrointestinal motility
(Horowitz et al., 2002), in this study the rate of gastric emptying
was comparable in diabetic and non-diabetic rats, suggesting
that gastroparesis did not develop in spite of constantly high
blood glucose level.
Despite of a huge research, there is no present data that could
end the debate on the controversy of effectiveness of current
opioid analgesics in the management of DNP. In addition,
only a few studies were carried out on the antinociceptive-
antiallodynic effects of opioids at advanced diabetes of 9–
12 weeks that at least could suit the clinical condition of
advanced neuropathic pain. To carry on, we examined the change
in the antinociceptive effects of the test compounds (14-O-
MeM6SU, fentanyl and morphine) in both naïve (weight match
control) and diabetic rats at 9 weeks after STZ-treatment. In
addition to the drug’s antinociception, the antiallodynic actions
of the test compounds were also determined. Keeping in mind,
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FIGURE 5 | The antagonist effect of s.c. co-administered NAL-M (10.6 µmol/kg) on the analgesic effect of s.c. 14-O-MeM6SU (A) and morphine (B) in STZ treated
neuropathic animals in doses that reversed the allodynia and elevated PPT on diabetic and non-diabetic animals. Data were obtained 60 min after the injection of
14-O-MeM6SU and 30 min in the case of morphine injection. Each value represents the mean in grams ± SEM. ∗p < 0.05 vs. diabetic baseline and saline treated
group. #p < 0.05 vs. weight match control group (one way ANOVA followed by Newman–Keuls post hoc test).
FIGURE 6 | The immunohistological assay shows reduction in MOR number in DRG (A,B) and spinal cord dorsal horn tissues (A,C) of STZ treated diabetic rats in
comparison with non-diabetic animals (n = 5). Scale bar = 20 µm for DRG and 40 µm for spinal cord section. Each value represents the mean ± SEM. ∗p < 0.05
Student t-test.
when we explain the antinociception, we refer to the change
in the paw thresholds of control and diabetic rats. On the
other hand, when speak about antiallodynic effects, we refer
to the effects of test compounds that only seen in rats with
hyperglycemia that developed tactile allodynia. Impairment in
the antinociceptive effect was seen only for systemic morphine.
This tendency is based on the calculated ED30 values where
morphine was 7 times less effective in diabetic animals than
non-diabetic ones, whereas fentanyl or 14-O-MeM6SU showed
no difference in the antinociceptive action between diabetic and
non-diabetic animals (Figure 3, ED30diabetic/ED30non−diabetic).
This indicates a significant reduction in the antinociceptive
effect of morphine, which is in accordance with previous studies
(Courteix et al., 1998; Cegielska-Perun et al., 2014). Yet, the
novel compound and fentanyl remained highly effective even in
neuropathic conditions.
Regarding to antiallodynic effect, our study is new from two
aspects. The first aspect is the novel compound but not fentanyl
or morphine at the present work circumstances produced
antiallodynic effect in doses devoid of an impact on naïve rats.
Frontiers in Pharmacology | www.frontiersin.org 10 April 2019 | Volume 10 | Article 347
fphar-10-00347 April 8, 2019 Time: 17:34 # 11
Balogh et al. Opioid Efficacy – Rat Diabetic Neuropathy
FIGURE 7 | [3H]DAMGO binding in membrane tissues from dorsal spinal cord
of diabetic and non-diabetic rats (n = 3–5). ∗p < 0.05; vs. non-diabetic control
group (∗∗p < 0.01). (Two-way ANOVA followed by Fisher’s LSD post hoc test.)
This statement is based on the following observations: 14-O-
MeM6SU (253 nmol/kg) but not fentanyl or morphine produced
significant antiallodynic action only in DNP and no impact on
PPTs of naive rats.
Previous studies by our and other groups reported on
the effects of different opioids in diabetic NP, though the
antiallodynic efficacy was varied (Courteix et al., 1998; Shaqura
et al., 2013, 2014; Rutten et al., 2014). Many studies reported on
the lowered opioid antinociceptive efficacy in animal neuropathic
models (Cegielska-Perun et al., 2014; Shaqura et al., 2014;
Yadlapalli et al., 2016). Some studies reported the ineffectiveness
of morphine even in doses up to 10 mg/kg (approximately
31 µmol/kg) 7 weeks following STZ treatment (Yamamoto et al.,
2009). Of note, in contrast to morphine, 14-O-MeM6SU or
fentanyl displayed equipotent antinociception in non-diabetic
and diabetic rats.
We further analyzed the peripheral antiallodynic component
of morphine and 14-O-MeM6SU in the presence of systemically
given NAL-M, because in our previous works, in inflammatory
pain models 14-O-MeM6SU in certain doses showed peripheral
antinociception (Lackó et al., 2016; Balogh et al., 2018). The
applied NAL-M dose has been reported previously for its
peripheral distribution (Bianchi et al., 1982; Lewanowitsch and
Irvine, 2002). Under the present experimental circumstances,
systemic NAL-M failed to affect the antiallodynic effect of
systemic 14-O-MeM6SU or morphine (Figure 5). Consequently,
if we accept that NAL-M does not penetrate the blood brain
barrier in the applied doses, then, MOR in CNS might mediate
the measured antinociceptive effect of higher systemic doses of
test compounds that abolished allodynia, in accordance with
previous studies (Zurek et al., 2001). A question might be raised
about the peripheral vs. central antiallodynic effect of fentanyl.
Regarding to this issue fentanyl has physiochemical properties
that allow it to readily access to the CNS following systemic
administration as described by previous studies (Fürst et al.,
2005). Therefore, involvement of central opioid system in the
antiallodynic effect of fentanyl is not a matter of debate.
The central opioid analgesic effect is originated from the
activation of opioid receptors in the spinal and supraspinal region
as described elsewhere (Pasternak, 1993). The analysis of MOR
functioning at both spinal and supraspinal levels was carried out
to elucidate the above mentioned and stand for our second aspect.
The second aspect is that, at the level of spinal cord, 14-
O-MeM6SU or fentanyl but not morphine caused remarkable
effect in G-protein coupling in spinal tissues prepared from
rats with DNP 9 weeks following STZ treatment (Figure 8 and
FIGURE 8 | Agonist activity of 14-O-MeMSU (A,D) compared to fentanyl (B,E) and morphine (C,F) in rat whole spinal cord membrane homogenates treated with
vehicle or STZ for 9 (A–C) or 12 weeks (D–F) after treatment in [35S]GTPγS binding assays. Figures represents the specific binding of [35S]GTPγS in the presence of
increasing concentrations (0.1 nM–10 µM) of the indicated ligands. Points represent means ± S.E.M. for at least three experiments performed in triplicate. “Basal”
on the x-axis indicates the basal activity of the monitored G-protein, which is measured in the absence of the compounds and also represents the total specific
binding of [35S]GTPγS. The level of basal activity was defined as 100% (indicated by dotted line). The calculated Emax and EC50 ± S.E.M. values are presented in
Table 1. ∗p < 0.05 diabetic vs. non-diabetic samples (∗∗p < 0.01; Two-way ANOVA, Fisher’s LSD post hoc test).
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TABLE 1 | Maximum G-protein efficacy (Emax ± SEM) and potency (EC50 ± SEM)
of 14-O-MeM6SU, compared to morphine and fentanyl in vehicle (non-diabetic)
and 9 and 12 weeks STZ treated (diabetic) rat spinal cord performed in
[35S]GTPγS binding assays.
Emax ± SEM (%) EC50 ± SEM (nM)
Non-diabetic Diabetic Non-diabetic Diabetic
9 weeks
14-O-
MeM6SU
141.4 ± 2###
(n = 6)
137.3 ± 2.47###
(n = 5)
35.08 ± 11.75
(n = 6)
43.35 ± 19.94
(n = 5)
Fentanyl 131.6 ± 2.55###
+ (n = 5)
129.5 ± 2.33###
+ (n = 6)
63.94 ± 41.93
(n = 5)
53.95 ± 36.81
(n = 6)
Morphine 124.4 ± 2.09
(n = 7)
115.4 ± 2.97∗∗
(n = 7)
N.D.1 N.D.1
12 weeks
14-O-
MeM6SU
135.5 ± 1.88##
(n = 6)
133.8 ± 2.4###
(n = 5)
14.96 ± 5.66
(n = 6)
43.45 ± 21.17
(n = 5)
Fentanyl 135.5 ± 1.25##
(n = 6)
128.1± 1.94##+∗∗
(n = 6)
56.89 ± 12.9
(n = 6)
78.7 ± 34.71
(n = 6)
Morphine 126.6 ± 2.12
(n = 4)
118.3 ± 1.41∗∗
(n = 6)
N.D.1 N.D.1
Values were calculated according to Figure 8. ∗ Indicates the significant difference
in diabetic samples compared to control (∗∗P < 0.01). + Indicates the significant
difference compared to 14-O-MeM6SU within control or diabetic samples
(+P < 0.05). # Indicates the significant difference compared to morphine within
control or diabetic samples (##P < 0.01; ###P < 0.001). 1Not determined, since
the EC50 values could not be interpreted. Two-way ANOVA followed by Fisher’s
LSD post hoc test.
TABLE 2 | Maximum G-protein efficacy (Emax ± SEM) and potency (EC50 ± SEM)
of 14-O-MeM6SU, compared to morphine and fentanyl in vehicle (non-diabetic)
and 9 and 12 weeks STZ (diabetic) treated rat brain performed in
[35S]GTPγS binding assays.
Emax ± SEM (%) EC50 ± SEM (nM)
Non-diabetic Diabetic Non-diabetic Diabetic
9 weeks
14-O-
MeM6SU
145.7 ± 2.4###
(n = 6)
140.7 ± 2.1
(n = 6)
29.51 ± 11.44
(n = 6)
33.19 ± 19.09
(n = 6)
Fentanyl 140.2 ± 2.67##
(n = 7)
134.8 ± 2.84
(n = 5)
36.64 ± 18.42
(n = 7)
32.02 ± 20.14
(n = 5)
Morphine 128.8 ± 2.65
(n = 7)
133.5 ± 4.85
(n = 6)
N.D.1 N.D.1
12 weeks
14-O-
MeM6SU
148.5 ± 3.59##
(n = 4)
146.1 ± 3.22#
(n = 5)
34.99 ± 17.74
(n = 4)
27.86 ± 13.87
(n = 5)
Fentanyl 149.7 ± 2.38##
(n = 5)
146.1 ± 3.51#
(n = 4)
197.7± 54.05+
(n = 5)
124.74 ± 55.64
(n = 4)
Morphine 135.2 ± 2.65
(n = 4)
135.6 ± 3.08
(n = 4)
N.D.1 N.D.1
Values were calculated according to Figure 9. # Indicates the significant difference
compared to morphine within control or diabetic samples (#P < 0.05; ##P < 0.01;
###P < 0.001). + indicates the significant difference compared to 14-O-MeM6SU
within control or diabetic samples (+P < 0.05). 1Not determined, since the
EC50 values could not be interpreted. Two-way ANOVA followed by Fisher’s LSD
post hoc test.
Table 1). Further extension of blood hyperglycemia impaired
both morphine and fentanyl induced MOR activation, though the
degree of impairment in the case of morphine was prominent.
In our previous work in rats with advanced (12 weeks) diabetic
neuropathy and mechanical hyperalgesia, we demonstrated
a decrease in fentanyl-mediated spinal antinociception in
mechanical hyperalgesia associated with reduced MOR number
and G-protein coupling in sensory neurons (Shaqura et al., 2013).
In the present work we also detected a decrease in MOR density
both in the DRG and the dorsal horn of the spinal cord of rats
with DNP (Figure 6). On the other hand, we have previously
proved that 14-O-MeM6SU has higher intrinsic efficacy than
morphine (Khalefa et al., 2012), meaning that even if there is
a decrease in MOR reserve it might activate MOR and produce
measurable analgesia.
The results presented herein proved that 14-O-MeM6SU and
fentanyl are opioids of high efficacy, because they could produce
significant G-protein activation in spinal cord homogenates from
diabetic rats after 9-12 of STZ treatment. In contrast to 14-O-
MeM6SU or fentanyl, morphine displayed very weak G-protein
activation at the same time points. Of note, fentanyl showed
significantly lower efficacy in all spinal samples compared to the
novel compound but was superior to morphine. On the other
hand, neither morphine nor 14-O-MeM6SU or fentanyl showed
any difference in efficacy at the supraspinal level of diabetic
rats compared to non-diabetic. Interestingly, 14-O-MeM6SU
and fentanyl, but not morphine, showed similar efficacy at
the spinal level in control and diabetic rat after 9 weeks.
Furthermore, activation of MOR by 14-O-MeM6SU was not
affected by developed diabetes and remained significantly higher
compared to the other test compounds. Our previous study
showed reduction in the analgesic action of fentanyl in diabetic
rats of 12 weeks. The impairment of fentanyl analgesia was
related to decrease in MOR functioning, as described previously
(Shaqura et al., 2013). At the present we can relate the difference
in G-protein coupling property of brain compared to the spinal
cord to the difference in their MOR reserve. It means that the
magnitude of action largely depends on the efficacy (intrinsic
activity) of test opioid agonists. Morphine has been reported
to display lower efficacy (partial agonist) either in isolated
organs hosting opioid receptors or G-protein activation assay
(Rónai et al., 2006; Al-Khrasani et al., 2007). In contrast to
morphine, 14-O-MeM6SU or fentanyl were found to be full
agonists (higher intrinsic activity) (Lacko et al., 2012; Khalefa
et al., 2013). Therefore, if the receptor reserve is decreased then
only opioids of high efficacy could show activity regardless of
circumstances in vitro or in vivo. Herein, the density of opioid
receptors was lower at the spinal level and no change was
observed in the brain of diabetic rats. In addition, MORs are
distributed in the pre- and postsynaptic membranes of primary
and secondary sensory neurons, respectively, that convey pain
toward the brain. Consequently, this condition (low spinal MOR
density) could affect the spinal analgesic action of low efficacy
opioids such as morphine.
[35S]GTPγS binding assays are used to demonstrate the
alterations in the G-protein activity in the presence of opioid
agonists. The activation of G-protein is the initial step of the
GPCR signaling pathway. Indeed, this activity was disrupted in
MOR receptors expressed in the spinal cord (see Results section:
The G-protein Coupling Activity of 14-O-MeM6SU, Fentanyl or
Frontiers in Pharmacology | www.frontiersin.org 12 April 2019 | Volume 10 | Article 347
fphar-10-00347 April 8, 2019 Time: 17:34 # 13
Balogh et al. Opioid Efficacy – Rat Diabetic Neuropathy
FIGURE 9 | Agonist activity of 14-O-MeMSU (A,D) compared to fentanyl (B,E) and morphine (C,F) in rat whole brain membrane homogenates treated with vehicle
or STZ 9 weeks (A–C) or 12 weeks (D–F) after treatment in [35S]GTPγS binding assays. Figures represents the specific binding of [35S]GTPγS in the presence of
increasing concentrations (0.1 nM–10 µM) of the indicated ligands. Points represent means ± S.E.M. for at least three experiments performed in triplicate. “Basal” on
the x-axis indicates the basal activity of the monitored G-protein, which is measured in the absence of the compounds and also represents the total specific binding
of [35S]GTPγS. The level of basal activity was defined as 100% (indicated by dotted line). The calculated Emax and EC50 ± S.E.M. values are presented in Table 2.
Morphine in Spinal Cord Homogenates Prepared From Diabetic
or Control Rats), which corresponds well with results seen
in immunohistochemistry and saturation binding experiments.
Signaling mechanism of morphine has been reported to engage
both G-protein coupling and β-arrestin recruitment. However,
at the present time we have no data on the mechanism of 14-
O-MeM6SU regarding to β-arrestin recruitment. Future studies
are needed to explore whether 14-O-MeM6SU is biased to
G-protein or β-arrestin.
The spinal cord is a crucial point in pain transduction
(Pasternak, 1993). At this pain traffic point MORs are found in
the presynaptic central terminals of primary afferent neurons,
which are the targets for spinally administered opioids and
other drugs prescribed for NP, like gabapentinoids (Perret and
Luo, 2009). These analgesic agents block the voltage gated
calcium channels (VGCCs), and consequently transmitters that
further process pain toward the brain. Since opioid receptors
are localized in both pre- and postsynaptic membrane of
primary afferent and secondary afferent fibers, respectively their
activation will result in the inhibition of transmitter release and
consequently the peripheral signal propagation toward the brain.
Therefore, we can hypothesize that 14-O-MeM6SU, a high
efficacy opioid indicated by high G-protein coupling, might
block the pain effectively at this point. Under the present
experimental conditions, morphine did produce weak G-protein
coupling in spinal homogenates from diabetic rats, so behaved
as a partial agonist, meaning that at higher doses its analgesic
action might be stemmed from the activation of opioid receptors
at the supraspinal level rather than opioid receptors at the
presynaptic site of central terminal of primary afferent. MOR
number apparently was low at the level of DRG and spinal dorsal
horn, in accordance with previous data that showed a significant
decrease in MOR in the spinal cord of animals with diabetic
neuropathy (Shaqura et al., 2013). Therefore, the supraspinal
region is largely responsible for morphine analgesia supported
by G-coupling in the present work and other in vivo studies
(Muranyi and Radak, 2008; Al-Khrasani et al., 2012). In addition,
advance in diabetes (12 weeks) could also affect the effect of
fentanyl on G-protein activation, though in contrast to morphine
it still produces significant effect in term of efficacy (Emax).
An important question might be raised on the impact of test
compounds on the respiratory functions. In our previous work
14-O-MeM6SU in a dose of 253 nmol/kg showed no respiratory
depression, yet in the present work could produce significant
antiallodynic action. On the other hand morphine or fentanyl
produced antiallodynic effects only in higher doses that are
well known to cause significant respiratory depression (Pazos
and Flórez, 1984; Hutchinson et al., 2008; Cavalla et al., 2015).
Taken together, the present study established the ineffectiveness
of morphine and in contrast to 14-O-MeM6SU proved change on
G-protein coupling between the 9th and 12th week of diabetes in
the case of fentanyl. Future studies are needed to explore the role
of spinal opioid receptors compared to supraspinal ones in the
inhibition of DNP. Of note, in the present work we did our best
to obtain our conclusion from one species (rats) applying in vivo
and vitro assays. The in vivo results were supported by G-protein
coupling and immunohistochemical assays. G-protein activation
is undoubtedly an important step to establish the response of the
cells to ligands. Immunohistochemistry is an important tool to
assess the change of tissue-based protein expression. Therefore,
the outcome of the present study hopefully will contribute to
better understanding the mechanisms underlying the variation
in the response of patients as well as animals with DNP to
current opioids.
In the light of above mentioned, the present study also could
shed light on the efficacy of opioids in the management of
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advanced diabetes (9 and 12 weeks) applying three different
opioid agonists: one novel and two are considered as classical
opioids of clinical values. Of note the test compounds
display different physiochemical profiles, efficacy and duration
of actions. Also proved that only diabetes of 12 weeks
long could discriminate between opioid analgesics of high
efficacy that had shown similarity in 9 weeks or earlier
stage of diabetes.
CONCLUSION
Large reduction in the antinociception of morphine but not of
fentanyl or 14-O-MeM6SU in diabetic rats compared to control
rats was observed.
Alterations in the antinociceptive effects of morphine and
fentanyl but not 14-O-MeM6SU were shown in diabetic
neuropathic rats.
Untreated diabetes results in reduced MOR G-protein
coupling by morphine and fentanyl but not 14-O-MeM6SU
at the level of spinal cord, key traffic point in the
pain transmission.
Advanced diabetes results in significant reduction in the
antiallodynic effects of partial agonists like morphine in
contrast to the opioid agonists with high efficacy: 14-O-
MeM6SU or fentanyl. Developing novel opioids with high
efficacy in the management of advanced painful diabetes is of
unmet medical needs.
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